Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$6.83
$10.15
$2.71
▼
$14.53
$333.92M2.4501,172 shs587,644 shs
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$0.95
$0.83
$0.49
▼
$2.25
$88.33M3.39120,056 shs208,398 shs
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
$3.03
$1.88
$0.39
▼
$4.19
$326.51M0.8619.06 million shs15.23 million shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$29.32
$22.80
$11.39
▼
$37.83
$340.41M0.47962,898 shs645,978 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
0.00%-2.29%-38.96%-27.65%+131.53%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.00%-9.52%+10.47%+34.01%-49.74%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
0.00%-26.46%+25.21%+348.89%+467.95%
Surrozen, Inc. stock logo
SRZN
Surrozen
0.00%-0.74%+28.82%+23.92%+117.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$6.83
$10.15
$2.71
▼
$14.53
$333.92M2.4501,172 shs587,644 shs
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$0.95
$0.83
$0.49
▼
$2.25
$88.33M3.39120,056 shs208,398 shs
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
$3.03
$1.88
$0.39
▼
$4.19
$326.51M0.8619.06 million shs15.23 million shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$29.32
$22.80
$11.39
▼
$37.83
$340.41M0.47962,898 shs645,978 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
0.00%-2.29%-38.96%-27.65%+131.53%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.00%-9.52%+10.47%+34.01%-49.74%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
0.00%-26.46%+25.21%+348.89%+467.95%
Surrozen, Inc. stock logo
SRZN
Surrozen
0.00%-0.74%+28.82%+23.92%+117.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.83
Moderate Buy$39.00471.01% Upside
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
1.00
SellN/AN/A
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
2.00
Hold$4.9061.72% Upside
Surrozen, Inc. stock logo
SRZN
Surrozen
2.71
Moderate Buy$48.3364.85% Upside

Current Analyst Ratings Breakdown

Latest CTOR, CYPH, SRZN, and ARTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/2/2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$40.00
9/25/2026
Surrozen, Inc. stock logo
SRZN
Surrozen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$44.00 ➝ $54.00
9/16/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/10/2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1.60 ➝ $4.90
8/31/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/27/2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$1.60
8/20/2026
Surrozen, Inc. stock logo
SRZN
Surrozen
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$51.00
8/20/2026
Surrozen, Inc. stock logo
SRZN
Surrozen
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$51.00
8/19/2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$0.90 ➝ $1.60
8/17/2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K1,335.67N/AN/A$4.48 per share1.52
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/A$0.54 per shareN/A
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/AN/AN/AN/A$1.83 per shareN/A
Surrozen, Inc. stock logo
SRZN
Surrozen
$3.48M97.82N/AN/A($19.21) per share-1.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$83.86M-$3.30N/AN/AN/AN/A-53.86%-48.16%11/11/2026 (Estimated)
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$24.76M-$0.47N/AN/AN/AN/A-102.98%-43.49%12/17/2026 (Estimated)
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
$4.82M$0.565.41N/AN/AN/A-20.76%-19.48%N/A
Surrozen, Inc. stock logo
SRZN
Surrozen
-$242.03M-$40.55N/AN/AN/A-2,885.33%N/A-93.62%11/6/2026 (Estimated)

Latest CTOR, CYPH, SRZN, and ARTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.07-$0.08-$0.01-$0.08$2.50 million$1.49 million
8/12/2026Q2 2026
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/A$0.18N/A$0.18N/AN/A
8/6/2026Q2 2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.6251-$0.63-$0.0049-$0.63N/AN/A
8/6/2026Q2 2026
Surrozen, Inc. stock logo
SRZN
Surrozen
-$1.29-$0.41+$0.88-$0.41$0.47 million$5.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/AN/A
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/AN/AN/AN/AN/A
Surrozen, Inc. stock logo
SRZN
Surrozen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
24.16
24.16
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.25
0.73
0.34
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
N/A
79.19
79.19
Surrozen, Inc. stock logo
SRZN
Surrozen
N/A
12.14
12.14

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
70.52%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
30.46%
Surrozen, Inc. stock logo
SRZN
Surrozen
66.57%

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
1.80%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
9.82%
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
3.50%
Surrozen, Inc. stock logo
SRZN
Surrozen
31.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
11548.89 million48.01 millionN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/A92.98 million83.85 millionN/A
Cypherpunk Technologies stock logo
CYPH
Cypherpunk Technologies
40107.76 million103.99 millionOptionable
Surrozen, Inc. stock logo
SRZN
Surrozen
4411.61 million7.93 millionNot Optionable

Recent News About These Companies

Financial Contrast: Surrozen (NASDAQ:SRZN) vs. Halozyme Therapeutics (NASDAQ:HALO)
October 3 at 5:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082854
Surrozen to Advance Potential Eye Drug into Clinical Development Following FDA Clearance
October 3 at 3:07 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/surrozen-advance-potential-eye-drug-125655316.html
Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema
October 2 at 12:04 PM  |  rttnews.comhttps://www.rttnews.com/3696162/surrozen-s-szn-8141-ind-cleared-by-fda-for-diabetic-macular-edema.aspx
Surrozen secures FDA clearance for SZN-8141 and $95.1 million financing
October 2 at 12:04 PM  |  grafa.comG
Surrozen advances diabetic macular edema candidate into clinic after IND clearance
October 2 at 12:04 PM  |  msn.comhttps://www.msn.com/en-us/news/other/surrozen-advances-diabetic-macular-edema-candidate-into-clinic-after-ind-clearance/ar-AA2dquiF
Surrozen Wins FDA IND Clearance for SZN-8141 Program
October 2 at 8:31 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surrozen-wins-fda-ind-clearance-for-szn-8141-program?utm_source=marketbeat.com&utm_medium=referral
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
October 2 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373778/0/en/surrozen-announces-fda-clearance-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema.html
Surrozen, Inc. (SRZN) Latest Stock News & Headlines - Yahoo Finance
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SRZN/news/
Surrozen, Inc. (NASDAQ:SRZN) Shares Shorted: Short Interest Up 51.9% in September
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-surrozen-inc-nasdaq-srzn-shares-shorted-short-interest-up-519-in-september-2026-10-01/
Surrozen, Inc. (SRZN) Stock Price, News, Quote & History - Yahoo Finance
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SRZN/latest-news/
FY2030 EPS Estimates for Surrozen Boosted by HC Wainwright
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063722
HC Wainwright Has Positive View of Surrozen FY2030 Earnings
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-positive-view-of-surrozen-fy2030-earnings-2026-09-29/
Surrozen, Inc. (NASDAQ:SRZN) Given Average Recommendation of "Moderate Buy" by Brokerages
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-surrozen-inc-nasdaq-srzn-given-average-recommendation-of-moderate-buy-by-brokerages-2026-09-18/
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947200-surrozen-inc-srzn-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surrozen (SRZN), Liquidia Technologies (LQDA) and Universal Health (UHS)
September 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LQDA/pressreleases/4530777/analysts-opinions-are-mixed-on-these-healthcare-stocks-surrozen-srzn-liquidia-technologies-lqda-and-universal-health-uhs/
Surrozen Submits IND Application For SZN-8141 In Diabetic Macular Edema
September 8, 2026  |  rttnews.comhttps://www.rttnews.com/3689238/surrozen-submits-ind-application-for-szn-8141-in-diabetic-macular-edema.aspx
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357649/0/en/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema.html
Surrozen to Present at Upcoming Healthcare Investor Conferences
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355487/0/en/surrozen-to-present-at-upcoming-healthcare-investor-conferences.html
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340707/0/en/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock
July 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-srzn-insider-buying-and-selling-2026-07-29/
Surrozen Inc
July 28, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/SRZN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Illustration of a server data center with an upward-trending chart line overlaid against a city skyline at sunset.
Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
By Thomas Hughes | September 8, 2026
Laptop displaying a U.S. Treasury yield curve chart on a desk with monitors showing stock market data.
3 ETFs That Could Move as Rate Expectations Shift
By Dan Schmidt | September 6, 2026
Illustration of a glowing semiconductor chip on a circuit board with a silicon wafer and data center server aisle.
Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
By Jeffrey Neal Johnson | September 9, 2026
Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$6.83 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$7.14 +0.31 (+4.54%)
As of 06:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Citius Oncology stock logo

Citius Oncology NASDAQ:CTOR

$0.95 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.92 -0.03 (-3.68%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Cypherpunk Technologies stock logo

Cypherpunk Technologies NASDAQ:CYPH

$3.03 0.00 (0.00%)
As of 10/2/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Surrozen stock logo

Surrozen NASDAQ:SRZN

$29.32 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$30.00 +0.68 (+2.32%)
As of 06:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas